Hopester,
I agree that far more data is needed. We've not been told that additional people have been dosed in Israel, but I've got to believe it's happening. Likewise we've not been told that they're starting to dose in Germany, but again I believe they should be. The question of how many is certainly unanswered, but I would hope we're looking at hundreds, even perhaps thousands, and if one or two weeks after dosing the results are as positive as for seven patients in Israel, I've got to believe that Internationally the use of our drug will be accepted.
I know that pneumonia is covered by our patents, I cannot say why the company didn't initially choose to run trials for it, perhaps it was because many do recover from it. In the case of coronavirus, many who go on the ventilator don't make it, certainly far more never go on a ventilator, but if it were up to me, those approaching the ventilator should be dosed, as well as all who're already on it. Prior to coronavirus, I'd suspect that a clinical trial for pneumonia would probably required thousands, perhaps even tens of thousands to be meaningful. With the greater probability of fatal pneumonia coming from coronavirus, I would hope the evidence from hundreds on ventilators to be sufficient to see it's benefits and permit its use, and PSTI should be paid for providing it. I don't know that they'll be paid on a per dose basis, or if the worlds governments will do bulk purchases to provide it to their people, but clearly PSTI should profit.
Gary
